74 related articles for article (PubMed ID: 7515735)
1. [Treatment of high malignancy lymphoma with intensive short-term chemotherapy using the MACOP-B regimen].
Delmer A; Bauduer F; Ruskoné-Fourmestraux A; Ajchenbaum-Cymbalista F; Delmas-Marsalet B; Rio B; Marie JP; Zittoun R
Bull Cancer; 1993 Sep; 80(9):808-15. PubMed ID: 7515735
[TBL] [Abstract][Full Text] [Related]
2. [NEO-MACOP-B chemotherapy for the treatment of advanced-stage aggressive non-Hodgkin's lymphoma].
Kohda K; Tsuji A; Takayanagi N; Takeda M; Hayashi S; Takimoto R; Fujisaki Y; Tsuji Y; Ezoe A; Nakazawa O
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2183-9. PubMed ID: 7694548
[TBL] [Abstract][Full Text] [Related]
3. Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas.
Gopal R; Nair R; Saikia TK; Soman CS; Dinshaw KA; Advani SH
J Assoc Physicians India; 1994 Oct; 42(10):781-4. PubMed ID: 7533151
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
Bernard M; Cartron G; Rachieru P; LeMevel A; Branger B; Le Maignan C; Berthou C; Ghandour C; Delwail V; Milpied N; Cassasus P; Celigny PS; Guyotat D; Lamy T; Desablens B;
Haematologica; 2005 Jun; 90(6):802-9. PubMed ID: 15951293
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
6. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
8. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
9. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Merli F; Federico M; Avanzini P; Ilariucci F; Stelitano C; Iannitto E; Colombi M; Vallisa D; Santagati G; Picinini L
Haematologica; 1998 Mar; 83(3):217-21. PubMed ID: 9573675
[TBL] [Abstract][Full Text] [Related]
10. Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
Hepatogastroenterology; 2007 Jun; 54(76):1285-8. PubMed ID: 17629090
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
[TBL] [Abstract][Full Text] [Related]
12. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
Vranovsky A; Ladicka M; Lakota J
Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
[TBL] [Abstract][Full Text] [Related]
14. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
[TBL] [Abstract][Full Text] [Related]
15. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
16. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
Mazzarotto R; Boso C; Vianello F; Aversa MS; Chiarion-Sileni V; Trentin L; Zambello R; Muzzio PC; Fiore D; Sotti G
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):823-9. PubMed ID: 17379431
[TBL] [Abstract][Full Text] [Related]
17. Non-Hodgkin's lymphoma associated with the acquired immunodeficiency syndrome.
Cáceres W
Bol Asoc Med P R; 1995; 87(10-12):158-61. PubMed ID: 8924158
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
19. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
